| Cover - USD ($) | 12 Months Ended | ||
| Dec. 31, 2019 | Apr. 16, 2020 | Jun. 28, 2019 | |
| Cover page. | |||
| Document Type | 10-K/A | ||
| Document Annual Report | true | ||
| Document Period End Date | Dec. 31, 2019 | ||
| Document Transition Report | false | ||
| Entity File Number | 001-33500 | ||
| Entity Registrant Name | Jazz Pharmaceuticals plc | ||
| Entity Incorporation, State or Country Code | L2 | ||
| Entity Tax Identification Number | 98-1032470 | ||
| Entity Address, Address Line One | Fifth Floor, Waterloo Exchange | ||
| Entity Address, Address Line Two | Waterloo Road | ||
| Entity Address, City or Town | Dublin 4 | ||
| Entity Address, Country | IE | ||
| Entity Address, Postal Zip Code | D04 E5W7 | ||
| Country Region | 353 | ||
| City Area Code | 1 | ||
| Local Phone Number | 634-7800 | ||
| Title of 12(b) Security | Ordinary shares, nominal value $0.0001 per share | ||
| Trading Symbol | JAZZ | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Large Accelerated Filer | ||
| Smaller Reporting Company | false | ||
| Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 7,869,781,340 | ||
| Entity Common Stock, Shares Outstanding (in shares) | 55,346,997 | ||
| Documents Incorporated by Reference | None. | ||
| Amendment Flag | true | ||
| Amendment Description | The registrant is filing this Amendment No. 1 to Annual Report on Form 10-K/A, or this Amendment (also referred to herein as this report), to amend the Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (Commission File Number 001-33500), or the 2019 Annual Report on Form 10-K, as filed by the registrant with the Securities and Exchange Commission, or the SEC, on February 25, 2020. The principal purpose of this Amendment is to include in Part III the information that was to be incorporated by reference from the proxy statement for the registrant’s 2020 Annual General Meeting of Shareholders, as well as to update certain of the information included on the cover page of the 2019 Annual Report on Form 10-K and in the list of exhibits included in Item 15 and the Exhibit Index of this report. This Amendment hereby amends the cover page, Part III, Items 10 through 14, and Part IV, Item 15 of the 2019 Annual Report on Form 10-K. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, new certifications by the registrant’s principal executive officer and principal financial officer are filed as exhibits to this Amendment. No attempt has been made in this Amendment to modify or update the other disclosures presented in the 2019 Annual Report on Form 10-K. This Amendment does not reflect events occurring after the filing of the original report (i.e., those events occurring after February 25, 2020) or modify or update those disclosures that may be affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the 2019 Annual Report on Form 10-K and the registrant’s other filings with the SEC. In this report, unless otherwise indicated or the context otherwise requires, all references to “Jazz Pharmaceuticals,” “the registrant,” “the company,” “we,” “us,” and “our” refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries. On January 18, 2012, the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma Public Limited Company, or Azur Pharma, were combined in a merger transaction, or the Azur Merger, in connection with which Azur Pharma was renamed Jazz Pharmaceuticals plc, and we became the parent company of and successor to Jazz Pharmaceuticals, Inc., with Jazz Pharmaceuticals, Inc. becoming our wholly owned subsidiary. | ||
| Document Fiscal Year Focus | 2019 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Central Index Key | 0001232524 | ||
| Current Fiscal Year End Date | --12-31 |
